49 research outputs found

    ่ฒž่ง€ไน‹ๆฒป์˜ ์ด๋ก ์„œ ใ€Š็พคๆ›ธๆฒป่ฆใ€‹

    Get PDF
    ๅ” ๅคชๅฎ— ์ด์„ธ๋ฏผ(599~649)์˜ ์–ธํ–‰์„ ๊ธฐ๋กํ•œ ์ฑ… ใ€Š่ฒž่ง€ๆ”ฟ่ฆใ€‹๋Š” ์—ญ๋Œ€๋กœ ๋™์•„์‹œ์•„ ๊ตฐ์™•๋“ค์˜ ๅธ็Ž‹ๅญธ ๊ต๊ณผ์„œ์˜€๋‹ค. ้š‹ๆœซๅ”ๅˆ์˜ ๋Œ€ํ˜ผ๋ž€์„ ์ˆ˜์Šตํ•˜๊ณ  ๋‹น ์™•์กฐ์˜ ๊ธฐํ‹€์„ ๊ณต๊ณ ํ•˜๊ฒŒ ๋‹ค์ง„ ๅ” ๅคชๅฎ—์˜ ์—…์ ์€ ๊ทธ ์ž์ฒด๋กœ ์ฒœํ•˜๋ฅผ ํ†ต์น˜ํ•˜๋Š” ์ตœ๊ณ  ๊ถŒ๋ ฅ์ž๋“ค์—๊ฒŒ ํ›Œ๋ฅญํ•œ ์ฐธ๊ณ ์˜ ์ฒด๊ณ„๋ฅผ ์ œ๊ณตํ–ˆ์„ ํ…Œ์ง€๋งŒ, ๅ” ๅคชๅฎ—์ด ์กฐ์ •์˜ ์‹ ํ•˜๋“ค๊ณผ ์ง„์ง€ํ•˜๊ฒŒ ํ† ๋ก ํ•˜๋ฉด์„œ ์น˜๊ตญ์˜ ๋ฐฉ๋ฒ•์„ ๋ชจ์ƒ‰ํ•˜๋˜ ๊ณผ์ •์„ ์ฃผ์ œ๋ณ„๋กœ ๋ถ„๋ฅ˜ํ•˜์—ฌ ํ‰์ดํ•œ ๋ฌธ์ฒด๋กœ ์ผ๋ชฉ์š”์—ฐํ•˜๊ฒŒ ์ •๋ฆฌํ•ด๋†“์€ ใ€Š่ฒž่ง€ๆ”ฟ่ฆใ€‹์˜ ๋งค๋ ฅ๋„ ์ดํ›„ ๅธ็Ž‹๋“ค์ด ์ด ์ฑ…์„ ์ฆ๊ฒจ ์ฝ๊ฒŒ ๋˜์—ˆ๋˜ ์ฃผ์š”ํ•œ ์ด์œ ์˜€์„ ๊ฒƒ์ด๋‹ค. ์‹ ํ•˜๋“ค์˜ ์ž…์žฅ์—์„œ๋„ ์ด ์ฑ…์ด ๊ตฐ์ฃผ์˜ ๋…๋‹จ์ ์ธ ๊ตญ์ •์šด์˜์„ ๊ฒฝ๊ณ„ํ•˜๊ณ  ๊ด€๋ฃŒ๋“ค์˜ ๊ฐ„์–ธ์„ ์ˆ˜์šฉํ•˜๋Š” ๋‚ด์šฉ์„ ํ’๋ถ€ํ•˜๊ฒŒ ๋‹ด๊ณ  ์žˆ๋‹ค๋Š” ์ ์—์„œ ๊ตฐ์ฃผ์—๊ฒŒ ์ ๊ทน์ ์œผ๋กœ ์ถ”์ฒœํ•  ๋งŒํ•œ ๋ฌธํ—Œ์ด์—ˆ๋‹ค. ์ด ๋•Œ๋ฌธ์— ใ€Š่ฒž่ง€ๆ”ฟ่ฆใ€‹๋Š” ์ค‘๊ตญ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์กฐ์„ ์ด๋‚˜ ์ผ๋ณธ์—์„œ๋„ ํ†ต์น˜์ž๋“ค์˜ ํ•„๋…์„œ ์ค‘ ํ•˜๋‚˜๋กœ ์ž๋ฆฌ ์žก๊ฒŒ ๋œ๋‹ค

    (The) quality of life in cancer patients

    No full text
    ์˜ํ•™๊ณผ/์„์‚ฌ[ํ•œ๊ธ€] ์˜ํ•™์˜ ๋ชจ๋“  ์น˜๋ฃŒ๋Š” ๊ถ๊ทน์ ์œผ๋กœ ์‚ด์˜ ์งˆ์„ ์ฆ์ง„์‹œํ‚ค๋Š” ๊ฒƒ์„ ๋ชฉ์ ์œผ๋กœ ํ•œ๋‹ค. ์„ ํ–‰์—ฐ๊ตฌ๊ฒฐ๊ณผ๋“ค์—์„œ ์•”ํ™˜์ž๊ฐ€ ๋Š๋ผ๋Š” ์‚ถ์˜ ์งˆ์ด ๊ฒฝ๊ณผ๋‚˜ ์˜ˆํ›„ ๋“ฑ์— ์žˆ์–ด ์ค‘์š”ํ•˜๋‹ค๋Š” ์ ์€ ์ถฉ๋ถ„ํžˆ ์ž…์ฆ๋˜๊ณ  ์žˆ๋‹ค. ์ด๋Ÿฌํ•œ ์ ์—์„œ ์•”ํ™˜์ž๊ฐ€ ์ง€๊ฐํ•˜๋Š” ์‚ถ์˜ ์งˆ๊ณผ ๊ทธ ํŠน์„ฑ์„ ๊ตฌ์ฒด์ ์œผ๋กœ ๋น„๊ต ํ‰๊ฐ€ํ•จ์œผ๋กœ์จ, ์งˆํ™˜์— ๋ณด๋‹ค ๋‚˜์€ ๋Œ€์ฒ˜๋ฅผ ํ•  ์ˆ˜ ์žˆ์„ ๊ฒƒ์ด๋‹ค. ์ด ์—ฐ๊ตฌ๋Š” ์•”ํ™˜์ž์˜ ์‚ถ์˜ ์งˆ์ด ๋‹ค๋ฅธ ์งˆ๋ณ‘์„ ๊ฐ€์ง„ ํ™˜์ž ๋ฐ ์งˆ๋ณ‘์ด ์—†๋Š” ๊ตฐ๊ณผ์˜ ์ฐจ์ด๋ฅผ ๋ฐํžˆ๊ณ ์ž ํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ๋ฐฉ๋ฒ•์œผ๋กœ 58๋ช…์˜ ์•”ํ™˜์ž๊ตฐ, 202๋ช…์˜ ์ผ๋ฐ˜ ํ™˜์ž๊ตฐ๊ณผ 229๋ช…์˜ ์งˆ๋ณ‘์ด ์—†๋Š” ์ •์ƒ์ธ๊ตฐ์„ ๋Œ€์ƒ์œผ๋กœ ํ•œ๊ตญ์–ดํŒ ์„ธ๊ณ„๋ณด๊ฑด ๊ธฐ๊ตฌ ์‚ถ์˜ ์งˆ ์ฒ™๋„(WHOQOL)๋ฅผ ์ด์šฉ, ์‚ถ์˜ ์งˆ์„ ํ‰๊ฐ€ํ•˜๊ฒŒ ํ•˜์—ฌ ๋น„๊ตํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ ๊ฒฐ๊ณผ, ์‚ถ์˜ ์งˆ ์ ์ˆ˜๊ฐ€ ์•”ํ™˜์ž๊ตฐ์ด ๊ฐ€์žฅ ๋‚ฎ์•˜๊ณ  ์ผ๋ฐ˜ ํ™˜์ž๊ตฐ, ์ •์ƒ์ธ๊ตฐ์˜ ์ˆœ์„œ๋ฅผ ๋ณด์˜€๋‹ค. ์ด๋Ÿฌํ•œ ๊ตฐ๊ฐ„์˜ ์ฐจ์ด๊ฐ€ ์‚ถ์˜ ์งˆ ์ ์ˆ˜์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ์˜์—ญ์€ ์‹ ์ฒด์  ์˜์—ญ(domain 1), ์‹ฌ๋ฆฌ์  ์˜์—ญ(domain 2), ๋…๋ฆฝ์„ฑ ์˜์—ญ(domain 3), ํ™˜๊ฒฝ์˜์—ญ(domain 5), ์˜์„ฑ ์˜์—ญ(do main 6)์ด์—ˆ์œผ๋ฉฐ ์‚ฌํšŒ ์˜์—ญ(domain 4)์—์„œ๋Š” ์˜ํ–ฅ์„ ๋ฏธ์น˜์ง€ ์•Š์•˜๋‹ค. ๊ทธ ์ค‘ ์•”ํ™˜์ž๊ตฐ์—์„œ ๊ฐ€์žฅ ๋‚ฎ์€ ์‚ถ์˜ ์งˆ ์ ์ˆ˜๋ฅผ ๋ณด์ธ ์˜์—ญ์€ ์‹ ์ฒด์  ์˜์—ญ(domain 1), ๋…๋ฆฝ์„ฑ ์˜์—ญ(domain 3)์ด์—ˆ๋‹ค. ์•”ํ™˜์ž๊ตฐ๊ณผ ์ผ๋ฐ˜ ํ™˜์ž๊ตฐ๊ฐ„์—์„œ ํ†ต๊ณ„์ ์œผ๋กœ ์ฐจ์ด๊ฐ€ ๋‚˜์ง€ ์•Š๋Š” ์˜์—ญ์€ ์‹ฌ๋ฆฌ์  ์˜์—ญ(domain 2)๊ณผ ํ™˜๊ฒฝ ์˜์—ญ(domain 5)์ด์—ˆ๋‹ค. ์˜์„ฑ ์˜์—ญ(domain 6)์—์„œ๋Š” ์•”ํ™˜์ž๊ตฐ๊ณผ ์ผ๋ฐ˜ ํ™˜์ž๊ตฐ์—์„œ๋งŒ ์ฐจ์ด๋ฅผ ๋ณด์˜€๋‹ค. ๊ฒฝ๋กœ๋ถ„์„ ๊ฒฐ๊ณผ ์ „๋ฐ˜์ ์ธ ์‚ถ์˜ ์งˆ๊ณผ ์‹ฌ๋ฆฌ์  ์˜์—ญ์ด ๋‹ค๋ฅธ ์˜์—ญ๋“ค์˜ ์˜ํ–ฅ์„ ๋งŽ์ด ๋ฐ›๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚˜ ์‹ฌ๋ฆฌ์ ์ธ ์‚ถ์˜ ์งˆ์ด ์ตœ์ข…์ ์œผ๋กœ ์ค‘์š”ํ•œ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋Š” ์งˆ๋ณ‘์˜ ์œ ๋ฌด์— ๋”ฐ๋ผ ์‚ถ์˜ ์งˆ์ด ๋‚˜๋น ์ง€๋ฉฐ, ์•”ํ™˜์ž์—๊ฒŒ ์‹ ์ฒด์  ๊ณ ํ†ต, ๋…๋ฆฝ์„ฑ ์œ ์ง€ ๊ทธ๋ฆฌ๊ณ  ์˜์„ฑ ๋ฌธ์ œ์— ๋ณด๋‹ค ๋งŽ์€ ๋„์›€์ด ํ•„์š”ํ•˜๋‹ค๊ณ  ํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ์ตœ์ข…์ ์œผ๋กœ ์‹ฌ๋ฆฌ์  ์‚ถ์˜ ์งˆ์ด ์ค‘์š”ํ•˜๋‹ค๋Š” ๊ฒƒ์„ ์‹œ์‚ฌํ•œ๋‹ค. [์˜๋ฌธ] All the treatments of medicine is toward to the goal of improvement of the quality of life. The results of previous studies proves that the quality of life in cancer patients have influence on the course and prognosis of the disease. From this view point, evaluating how the cancer patients percept one's quality of life and comparing its characteristics, will make better interventions possible for the disease. This study is proposed to compare the quality of life, in cancer patients with the patients of other disease group, and the normal person group. In our study 58 cancer Patients, 202 patients of different diseases, 228 normal persons, assessed by WHOQOL, Korea version. underwent the evaluation the quality of life. The results of this study came out that the score of the cancer patient group was the lowest, followed by the patients of different diseases and the normal persons. These difference between groups were influenced by the physical domain(domain1), the psychological domain(domain2), the independent domain(domain3), the environmental domain(domain5), the spiritual domain (domain6), while the social domain(domain4) showed no difference. Among these domains, the physical domain(domain1 ) and the independent domain(domain3) showed the lowest scores in cancer patients. The psychological domain (domain2) and the environmental domain (domain5) showed no statistical difference between the cancer patients and the patients of other diseases. The statistical results through path analysis showed that the general quality of life and the psychological domain (domain2) were more influenced by other domains, suggesting that the psychological quality of life is the most important. These results shows that the quality of life is influenced by the presence of an illness, and suggest an intervention for physical pain, maintenance of independence and spiritual problems, and finally that the psychological quality of life is most important.restrictio

    Dynamics of the modified billiard problem

    No full text
    Maste

    ๊ฐ„์•”์ข…์—์„œ ERฮฑ์— ์˜ํ•œ IL-6, EpCAM, K19์˜ ๋ฐœํ˜„์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ

    No full text
    Dept. of Medical Science/์„์‚ฌThe expression of โ€œstemnessโ€-related markers in Hepatocellular carcinoma (HCC) was recently reported to be associated with more aggressive biological behavior and poor prognoses. Epithelial mesenchymal transition (EMT) was previously known to be involved in the generation of cancer stem cells. HCCs occur mainly in men, and estrogen and estrogen receptor alpha (ERฮฑ) were reported to play a protective role in HCC development by inhibiting secretion of IL-6, which is capable of inducing EMT. In this study, the role of ERฮฑ on the expression of cancer stem cell markers (EpCAM and keratin (K19), IL-6, EMT markers (Snail and Twist) as well as the biological behavior of HCC was investigated in both HCC cell lines and human HCC tissue samples. In PLC/PRF/5 and SNU423 cell lines, EpCAM-positive and EpCAM-negative cells were sorted by flow cytometry. ERฮฑ mRNA level was significantly higher in the EpCAM-negative cell fractions than in the EpCAM-positive cell fractions of both cell lines (P < 0.05). Snail mRNA level and Twist mRNA level were significantly higher (P < 0.05) (P = 0.06) in the EpCAM-positive cell fractions than in the EpCAM-negative cell2 fractions of both cell lines. IL-6 mRNA levels were significantly higher in the EpCAM-positive cell fractions than in the EpCAM-negative cell fractions of SNU423 cells (P = 0.03), whereas it was not detected in PLC/PRF/5 cells. Overexpression of ERฮฑ by transfection of pEGEF-C1-ERฮฑ plasmids showed a significant reduction of EpCAM and K19 expression levels in PLC/PRF/5 and SNU423 cell lines at both the mRNA and protein level (P < 0.05). Interestingly, overexpression of ERฮฑ reduced IL-6 expression at both the mRNA and protein level in SNU423 cells. However, Snail and Twist expression demonstrated no significant change after ERฮฑ overexpression in both cell lines. Overexpression of ERฮฑ significantly reduced the activities of cell proliferation, invasion and migration in both cell lines compared to the control group. We also studied 64 human HCC tissues; ERฮฑ type was evaluated by RT-PCR, and the mRNA expression levels of ERฮฑ, EpCAM, K19, IL-6, Snail and Twist were studied by real-time RT-PCR. The protein expression of EpCAM and K19 was also detected by immunohistochemical stain. Their expression levels were correlated with clinicopathologic features. HCC patients with the ERฮฑ wild type showed significantly higher mRNA levels of ERฮฑ; lower mRNA levels of EpCAM, K19 and IL-6; and lower protein expression of EpCAM and K19, compared to those with the ERฮฑ variant type (P < 0.05 in all); whereas there was no significant difference in mRNA levels of Snail and Twist between the two groups. HCC patients with the ERฮฑ variant type showed3higher incidences of portal vein invasion (P = 0.008), microvascular invasion (P = 0.024), and poor differentiation (P = 0.015), compared to those with the ERฮฑ wild type. Similarly, HCC patients with low ERฮฑ mRNA expression (lower 50%) showed higher portal vein invasion (P = 0.021) and microvascular invasion (P = 0.007) than those with high ERฮฑ mRNA expression (upper 50%). There were no significant differences in disease free survival and overall survival according ERฮฑ type and expression levels of ERฮฑ, IL-6, Snail, Twist, EpCAM and K19 at the mRNA or protein level. In conclusion, these data suggest low ERฮฑ mRNA expression and variant-ERฮฑ type are involved in the aggressive biological behavior of HCC, demonstrating high expressions of EpCAM, K19 and IL-6 in both HCC cell lines and HCC patients.ope

    ้ญๆ™‰ๅ—ๅŒ—ๆœ ๅฟ—ๆ€ช์˜ ์ƒ์ƒ๋ ฅ ์—ฐ๊ตฌ : ๅฟ—ๆ€ช ์—ฐ๊ตฌ์˜ ํ†ตํ•ฉ์  ๋ฐฉ๋ฒ• ๋ชจ์ƒ‰

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์ค‘์–ด์ค‘๋ฌธํ•™๊ณผ ๋ฌธํ•™ ์ „๊ณต,2001.Maste

    Visualization of endogenous p53 gene expression using sodium iodide symporter

    No full text
    Thesis (master`s)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :ํ˜‘๋™๊ณผ์ • ์ข…์–‘์ƒ๋ฌผํ•™์ „๊ณต,2004.Thesis (master`s)-

    ๋งˆ์šฐ์Šค ๋ชจ๋ธ์—์„œ ์•ŒํŒŒํƒœ์•„๋‹จ๋ฐฑ ์ธํ•ธ์„œํ”„๋กœ๋ชจํ„ฐ๋ฅผ ์ด์šฉํ•œ ๋ฆฌํฌํ„ฐ์œ ์ „์ž ๋ฐœํ˜„์˜ ๊ฐ„์•” ํ‘œ์ ํ™”

    No full text
    Thesis(doctors) --์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :ํ˜‘๋™๊ณผ์ •(์ข…์–‘์ƒ๋ฌผํ•™์ „๊ณต),2009.2.Docto

    Separatrix map and anti-integrability

    No full text
    Docto

    A Study on the Compilation and Significance of the Thirteen Classics Collation in Qing Dynasty

    No full text

    Recent Advance in the Treatment of Hypertension

    No full text
    Hypertension is one of the most significant but modifiable risk factors for cardiovascular disease. Previous clinical trial clearly showed that blood pressure reduction effectively decreased the incidence of cardiovascular and cerebrovascular events. Despite the improvement of hypertension treatment, the overall control rate of hypertension has not yet been clearly improved. The proportion of hypertensive patients who have their blood pressure controlled has increased dramatically during the past several decades; however, a lot of patients still did not reach the optima goal. In addition, other cardiovascular risk factors such as dyslipidemia, diabetes, and chronic kidney disease rapidly increased recently. As such, the proper control of the risk factors is much more important in high risk hypertensive patients. The control of hypertension continues to be inadequate despite the effective, well-tolerated medications. The control rates are even worse among the high risk patients, to whom target blood-pressure levels of 130/80 mm Hg or lower are recommended. In order to improve the level of blood pressure control in the population, we should enhance the awareness and treatment of hypertension through public health education. In addition, aggressive combination therapy including diuretics, overcoming therapeutic inertia, and screening for primary aldosteronism is warranted in all the hypertensive patients. Novel therapeutic approach for hypertension such as immunization against angiotensin II or renal denervation has gained much attention. In condusion, despite recent advance in pharmacological therapeutics, the rate of hypertension control is still far from satisfactory. Lower treatment thresholds and more intensive treatment contribute to better hypertension control. In particular, much more efforts are needed to encourage the use of low-cost thiazide diuretics as antihypertensive agents in patients taking more than three anti-hypertensive medications.Chobanian AV, 2009, NEW ENGL J MED, V361, P878Jamerson K, 2008, NEW ENGL J MED, V359, P2417Parati G, 2008, J HYPERTENS, V26, P1505Beckett NS, 2008, NEW ENGL J MED, V358, P1887Mancia G, 2007, J HYPERTENS, V25, P1105Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059Okonofua EC, 2006, HYPERTENSION, V47, P345, DOI 10.1161/01.HYP.0000200702.76436.4b2006, HYPERTENS RES S, V29, pS1Elliott WJ, 2004, HYPERTENSION, V44, P800, DOI 10.1161/01.HYP.0000146909.69161.8cJulius S, 2004, LANCET, V363, P2022Staessen JA, 2004, JAMA-J AM MED ASSOC, V291, P955
    corecore